Aptose Biosciences Inc. (APTOF): Nasdaq/NYSE listing notice — Aptose receives Nasdaq delisting notice for equity non-compliance; shares to be delisted Apr 2

Aptose Biosciences Inc.

Nasdaq determined to delist Aptose effective April 2, 2025 for failure to meet minimum stockholder equity requirement under Rule 5550(b)(1).
Company received the delisting notice on March 31, 2025; will review options including appeal.
Aptose intends to continue executing business plan and seek listing on a U.S. national securities exchange.
Common shares remain listed on the Toronto Stock Exchange (TSX) under symbol 'APS'.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Aptose Biosciences Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

March 31, 2025, Aptose Biosciences Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not regained compliance with Nasdaq’s minimum stockholder equity requirement in Listing Rule 5550(b)(1), Nasdaq determined to delist the Company’s securities from The Nasdaq Stock Market, effective on April 2, 2025. The Company and board of directors will review all available options, including an appeal to the determination, but will continue to execute its business plan and will seek to list on a U.S. national securities exchange at the ap

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-072397

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.